{
  "id": 18107853,
  "title": "Cascaded Dual-Targeting (WTW/TAT) Liposomes Delivery DOX for Precision Glioblastoma Treatment",
  "url": "https://urgent.news/2026/11/04/cascaded-dual-targeting-wtw-tat-liposomes-delivery-dox-for-precision",
  "topic": "science",
  "section": "Science",
  "published": "2026-11-04T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.11.02.760854v1?rss=1"
  },
  "original_language": "en",
  "account": "Glioblastoma (GBM) has proven challenging to treat due to the blood-brain barrier (BBB) and blood-tumor barrier (BTB) severely restricting drug delivery into tumor tissue. To overcome these delivery challenges, researchers constructed a dual-targeted liposomal nanoplatform called WT-LIP. This nanoplatform incorporates a WTW dual-targeting peptide to facilitate receptor-mediated BBB transcytosis and specificity to GBM, as well as a TAT peptide to enhance post-barrier penetration and tumor-cell uptake, allowing for sequential barrier crossing and targeted GBM treatment.\n\nThe DOX-loaded WT-LIP demonstrated heightened endothelial transport in vitro, achieving a permeated dose of 60.74 ± 2.14% at 480 minutes. In a BBB/GBM co-culture, this nanoplatform exhibited deeper transendothelial penetration and greater downstream tumor killing. In orthotopic U251-luc models, DiD-labeled WT-LIP showed enhanced brain/tumor accumulation (G/B = 2.16 ± 0.06). Moreover, DOX@WT-LIP markedly suppressed tumor growth by 74.92%, improved survival, and presented comparatively reduced systemic toxicity. This study highlights a ligand-guided strategy that combines efficient BBB transport with tumor-selective delivery to enhance GBM chemotherapy.",
  "summary": "Glioblastoma (GBM) remains difficult to treat because the blood-brain barrier (BBB) and blood-tumor barrier (BTB) severely limit drug transport into tumor tissue. To address these delivery constraints, we developed a dual-targeted liposomal nanoplatform (WT-LIP) that integrates a WTW dual-targeting peptide to promote receptor-mediated BBB transcytosis and specificity to GBM and a TAT peptide to…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}